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Abstract
Purpose Many postmenopausal women desire non-phar-
maceutical alternatives to hormone therapy for protection
against osteoporosis. Soybean isoflavones, especially gen-
istein, are being studied for this purpose. This study
examined the effects of synthetic genistein in combination
with other potential bone-protective dietary molecules on
bone mineral density (BMD) in early postmenopausal
women.
Methods In this 6-month double-blind pilot study, 70
subjects were randomized to receive daily either calcium
only or the geniVidaTM bone blend (GBB), which consisted
of genistein (30 mg/days), vitamin D3 (800 IU/days),
vitamin K1 (150 lg/days) and polyunsaturated fatty acids
(1 g polyunsaturated fatty acids as ethyl ester: eicosapen-
taenoic acid/docosahexaenoic acid ratio = *2/1). Markers
of bone resorption and formation and BMD at the femoral
neck, lumbar spine, Ward’s triangle, trochanter and inter-
trochanter, total hip and whole body were assessed.
Results Subjects supplemented with the GBB (n = 30)
maintained femoral neck BMD, whereas in the placebo
group (n = 28), BMD significantly decreased (p = 0.007).
There was also a significant difference (p \ 0.05) in BMD
between the groups at Ward’s triangle in favor of the GBB
group. Bone-specific alkaline phosphatase and N-telopep-
tide significantly increased in the GBB group in
comparison with those in baseline and in the placebo
group. The GBB was well tolerated, and there were no
significant differences in adverse events between groups.
Conclusions The GBB may help to prevent osteoporosis
and reduce fracture risk, at least at the hip, in postmeno-
pausal women. Larger and longer-term clinical trials are
warranted.
Keywords Genistein  Osteoporosis  Clinical trial 
Isoflavones  Bone mineral density  Safety
Introduction
In response to declining estrogen levels, women can lose
substantial amounts of bone mass in the decade following
menopause, which markedly increases their fracture risk
[1]. Until 2002, postmenopausal women were typically
prescribed hormone therapy (HT) if they were considered
to be at risk of developing osteoporosis. Although research
from the Women’s Health Initiative Trial confirmed that
HT reduces postmenopausal bone loss and hip fracture risk
[2], the results, along with findings from several other
large-scale studies, have also raised safety concerns about
the use of HT [3, 4]. These concerns have led to a dramatic
decline in HT use [5] and the need to identify non-hor-
monal anti-osteoporotic agents.
One widely studied non-pharmaceutical alternative for
promoting postmenopausal bone health is isoflavones;
among commonly consumed foods, they are found in
physiologically relevant amounts only in the soybean and
soyfoods. Isoflavones are present in soybeans almost
exclusively as glycosides, and the three aglycone isoflav-
ones genistein, daidzein and glycitein and their respective
glycosides account for approximately 50, 40 and 10% of
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total isoflavone content, respectively [6]. Mean isoflavone
intake in western countries is typically \3 mg/days [7],
whereas in Japan, daily intake of approximately 30–50 mg
can be achieved [8].
In general, isoflavones are considered to be phytoes-
trogens, because some members were shown to bind to
transactivate estrogen receptors and to initiate gene
expression [9]. Initial speculation about their efficacy was
based on their estrogen-like properties and early research
showing that the chemically synthesized isoflavone struc-
turally derivatized drug, ipriflavone, exerted skeletal ben-
efits [10]. The results of prospective epidemiologic studies
conducted in Shanghai [11] and Singapore [12] seem to
support the efficacy of isoflavones, as high soy intake in
these studies was associated with approximately 30%
reductions in fracture risk. However, the[25 clinical trials
that have examined the effects of isoflavones on bone
mineral density (BMD) have produced mixed results,
although two out of three recently published meta-analyses
found that soy isoflavones reduced bone loss at the lumbar
spine [13–15]. However, only four studies, the 3-year
Italian trial by Marini et al. [16], the 2- and 3-year US
studies by Levis et al. [17] and Alekel et al. [18], respec-
tively, and the 2-year Taiwanese study by Tai et al. [19]
were more than 1 year in duration. In the study by Marini
et al. [16], there were dramatic increases in postmeno-
pausal spinal and hip BMD after genistein supplementa-
tion, whereas in the other three studies, there was little
evidence that soy isoflavones produced skeletal benefits
[17–19].
To substantially reduce the risk of a chronic disease such
as osteoporosis, through lifestyle and dietary intervention,
requires the adoption of a comprehensive approach. Evi-
dence suggests that a combination of potentially bone-
protective dietary agents working through different mech-
anisms is more likely to result in a substantial benefit than
any single agent alone. For example, dietary protein is
viewed as beneficial for bone when sufficient dietary cal-
cium is consumed, but possibly harmful when it is not [20].
Also, vitamin D enhances the absorption of calcium and
may have independent skeletal benefits [21]. There is also
evidence that vitamin K is needed for c-carboxylation of
specific glutamic acids which converts 3 glutamic acid
(Glu) residues in osteocalcin (OC) to c-carboxyglutamic
acid (Gla) [22, 23], an essential structural modification for
the integration of osteocalcin into the bone matrix. Finally,
supplementation with long-chain omega-3 fatty acids
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) may reduce bone loss [24]. In mice, isoflavones and
fish oil additively induced parameters of bone structure and
increased bone mass synergistically in an ovariectomy-
induced bone loss model [22].
It is reasonable to speculate that when a combination of
agents is used, the amount of isoflavones required for
efficacy may be reduced. Therefore, we decided to conduct
a pilot study using geniVidaTM to determine whether a
physiological dose of genistein (30 mg/days), when com-
bined with other bioactives, will favorably impact bone
health in postmenopausal women. This dose of genistein is
in line with the mean intake of genistein among older
Japanese following a traditional diet [8]. This pilot inter-
vention study was conducted to generate data on the impact
of a genistein bone blend (GBB) on bone loss in early
postmenopausal women. Should efficacy be demonstrated,
the data could be used as a basis for designing a larger and
longer follow-up study.
Subjects and methods
Study design and trial supplementation
In this randomized, double-blind, placebo-controlled,
6-month pilot intervention study, the effect of a combina-
tion of genistein (30 mg/days), vitamin D3 (800 IU/days),
vitamin K1 (150 lg/days) and polyunsaturated fatty acids
1 g (PUFAs) as ethyl ester: EPA/DHA ratio = *2/1) on
bone health in postmenopausal women was investigated.
The protocol, informed consent form and advertisement for
subjects were approved by the Creighton University insti-
tutional Review Board (IRB) (no. 06–14202). The study
was conducted in accordance with Good Clinical Practice
Guidelines from the International Conference of Harmo-
nization and was registered at ClinicalTrial.gov (NCT
00698984).
Genistein, vitamin K1 and D3 and PUFAs were manu-
factured by DSM Nutritional Products, Ltd. (Kaiseraugst,
Switzerland), and capsule production (active and placebo)
as well as packaging and labeling took place at Intergel
Division, IVC Industries Inc., NJ (USA), under GMP
requirements and control. One soft-gelatin geniVidaTM
bone blend (GBB) capsule contained 15 mg genistein
(geniVida 99.1% genistein), 500 mg PUFAs (ROPUFA
75 n-3 Ethyl Ester), 75 lg vitamin K1 (99.7% phylloqui-
none) and 400 IU vitamin D3 (100% cholecalciferol)
together with corn oil and bees wax. Placebo capsules
contained only corn oil and bees wax.
Two capsules were taken per day in the morning toge-
ther with breakfast. In addition, one calcium carbonate
tablet containing 500 mg elemental calcium (Ost-Cal 500,
Goldine) was taken daily with either the placebo or GBB.
Supplementation began on the day after the baseline visit
(visit 1) and ended the morning before visit 3, 6 months
after visit 1.
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Randomization and blinding
Four-block randomization was performed by an employee
of DSM Nutritional Products Ltd., who was not involved in
the study. The randomization list was provided to Intergel
Division, IVC Industries Inc., for packaging and placement
of capsules into bottles and bottle labeling. Bottles with
randomization code numbers, which were shipped to
Creighton University, were dispensed to study subjects in
sequenced numbers. Unblinding occurred after all data
management procedures were completed. Only emergency
envelopes were located at the study site. The randomiza-
tion code was kept locked at the safety management
company (United BioSource Corporation (UBC), Geneva,
Switzerland). Subject identification was written on the
appropriate bottles and entered into the subject enrollment
log along with the randomization code.
Compliance
Study personnel dispensed supplements together with a
personal diary in which the subjects documented the date
and time of supplement use. Compliance was assessed on
the basis of pill count. Subjects were considered compliant
if 80% of the required number of pills was taken. Plasma
genistein concentrations measured at baseline and at 3 and
6 months were used as a secondary confirmation of com-
pliance but were not used as a basis for classifying subjects
as compliant or non-compliant.
Procedures
Before the subjects were invited for the pre-study exami-
nation, a brief telephone screen was conducted to deter-
mine whether they were within the study age range,
C1 year postmenopausal, and satisfied other inclusion/
exclusion criteria. Candidates who successfully completed
the telephone screening interview were scheduled for the
pre-study examination. In the pre-study examination,
which took place 1–2 months prior to study start, subject
eligibility was again determined. Subjects signed an
informed consent form prior to the pre-study examination
being performed.
After successful completion of the pre-study exami-
nation, volunteers were enrolled into the study, starting
with a 2-week run-in period during which time they
received the placebo. During the run-in period, the vol-
unteers familiarized themselves with the study procedures
and the dietary guidelines to which they were expected to
adhere. If the subjects successfully completed the run-in,
they were asked to sign a second informed consent for
study participation as well as to allow disclosure of per-
sonal data. They were then randomly enrolled into either
the placebo or GBB group and provided the appropriate
capsules.
Each subject had 5 visits (pre-study examination, start of
run-in, visits 1, 2 and 3) and received 6 phone calls
(screening and months 1, 2, 4 5 and follow-up) over a
period of 7–9 months. They were instructed to maintain
their normal diet and exercise routine. Telephone calls
between visits allowed compliance to study protocol to be
assessed. Fifteen days after the final visit, subjects were
contacted by phone to identify any changes in health status
since the final visit.
At visits 1, 2 and 3, bone markers (see below), plasma
genistein, 25-hydroxyvitamin D3 (25(OH)D) and phyllo-
quinone concentrations, dietary records and physical
activity levels were assessed, and diet counseling was
conducted. BMD was measured at baseline and visit 3 and
safety parameters at screening and visit 3.
Study subjects, recruitment, selection and disposition
Subjects were recruited between January 2007 and April
2008 by the research team from the Creighton University
Osteoporosis Research Center. Eligibility was based on
inclusion/exclusion criteria determined by physical exami-
nation, medical history, electrocardiogram (ECG), mam-
mogram, trans-vaginal ultrasound, BMD, clinical laboratory,
serology and drug and thrombophilia screening. Inclusion
criteria were healthy early postmenopausal women between
the ages of 45 and 55 years, 1–3 years since the last spon-
taneous menstrual bleeding and follicle-stimulating hormone
(FSH) and 17b-estradiol (E2) concentrations[75 IU/mL and
\20 ng/L, respectively, natural menopause or total hyster-
ectomy, and smoking \10 cigarettes/days.
Exclusion criteria were T-score \–2.5 at total hip and
spine (either or both), body mass index (BMI)[30 or\21,
use of HT within the previous 6 months, use of any drug
that might interfere with bone metabolism within the pre-
vious 12 months, extreme dietary habits, use of dietary
supplements while on study except multi-vitamins, total
genistein blood concentrations [100 ng/mL measured at
pre-study examination, unexplained weight loss or weight
gain of[5 kg in the 3 months prior to the study, history of
liver or pancreatic diseases, cardiovascular disease, history
of breast cancer, endometrial cancer or other malignancy
except basal and squamous cell skin cancer, history of
thromboembolism, any fractures within the past year
except for fingers, toes and facial bones, susceptibility to
fractures, endometrial thickness [6 mm, endometrial pol-
yps, insulin-dependent diabetes mellitus, any condition that
might interfere with the absorption of the investigational
product, co-medications. A total of 70 women were
enrolled and randomly assigned to supplementation groups
(Fig. 1).




BMD measurements at the femoral neck, lumbar spine,
Ward’s triangle, trochanter and intertrochanter, total hip
and whole body were made by dual-energy X-ray absorp-
tiometry (DXA) with a Hologic 4500 instrument (Hologic
Inc. Waltham, MA). The densitometers in the Osteoporosis
Research Center were operated from a core densitometry
laboratory by certified radiological technicians. Densi-
tometry scans were performed according to Osteoporosis
Research Center Standard Operating Procedures based on
Hologic training. To obtain DXA measurements, subjects
were placed in the supine position on a padded table while
a scanning arm passed back and forth over their entire
body. Radiation exposure was trivial and judged to be
acceptable by the Internal Review Board.
The coefficient of variation of the Hologic 4500 at the
Creighton University Osteoporosis Research Center is
1.1% at the spine and 1.3% at the hip. Measurements at
baseline and 6 months were duplicated (with repositioning
at each measurement), and the average of both measure-
ments was used for statistical analyses.
Anthropometry, diet and physical activity
Body composition (fat mass and lean body mass) was
calculated from DXA whole-body scans. Diets and physi-
cal activity were assessed via 3-day diaries. To complete
the diet diary, subjects were asked to record everything
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Fig. 1 Subject disposition
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consecutive). The dietician reviewed with the subjects how
to determine portion sizes. The 3-day diaries were analyzed
by a dietician using The Food Processor Nutrition and
Fitness Software (Version 7.8, 2001, ESHA Research,
Salem, OR). Physical activity was assessed using a portion
of the Paffenbarger activity questionnaire [25]. Subjects
were asked to estimate the number of hours each day that
they spent in various levels of physical activity.
Biological samples
Bone markers: Plasma bone-specific alkaline phosphatase
(BAP) was determined using a Beckman Coulter Access
Immunoassay System by Chemiluminescent Immunoassay,
and urinary N-telopeptide (Ntx) was determined by
Immunochemical method suing Ortho Diagnostics Vitros
Analysis.
Total osteocalcin (OC) in plasma was determined by a
solid-phase immuno-radiometric assay (Cis Bio Interna-
tional, France). Plasma concentration of undercarboxylated
osteocalcin (ucOC) was determined by modification of the
hydroxyapatite binding assay at Tufts University (Sarah
Booth, Jean Mayer USDA Human Nutrition Research) [26].
Deoxypyridinoline (DPD) in urine was determined by
enzyme immunoassay (EIA), and osteoprotegerin (OPG) and
receptor activator of nuclear factor kappa B ligand (RANKL)
were determined using an enzyme-linked immunoassay.
Genistein: Ten milliliter of venous blood was drawn into
tubes containing EDTA and centrifuged at 3,000 rpm for
10 min at 4 C. Plasma was pipetted and aliquoted into two
propylene tubes (1.5 mL each) and stored at -20 C. Free
and total (sum of unconjugated and conjugated) genistein
was determined by LC/MS at DSM Nutritional Products
Ltd., Kaiseraugst, Switzerland.
Phylloquinone: Plasma vitamin K concentration was
determined by reversed-phase high-performance liquid
chromatography at Tufts University (Sarah Booth, Jean
Mayer USDA Human Nutrition Research Center on Aging).
25-hydroxyvitamin D3 (25(OH)D): Plasma 25(OH)D
was measured by radioimmunoassay (RIA) at a certified
clinical laboratory.
EPA and DHA: Serum EPA and DHA were measured by
GC-FID and HPLC–MS (Agilent Q-TOF 6,530 High res-
olution mass spectrometer) at DSM Nutritional Products
Ltd., Kaiseraugst, Switzerland.
Clinical blood chemistry and urine analysis: Plasma
samples were used for the analysis of hormones (E2,
parathyroid hormone, FSH, luteinizing hormone and
thyroid stimulating hormone), lipids (total cholesterol,
triglycerides, HDL, VLDL cholesterol, LDL cholesterol),
hematology, HbA1c, coagulation factors, serology (hepa-
titis B and C) and thrombophilia screening. Urine elec-
trolytes were determined by certified clinical laboratories
according to clinically accepted standardized analytic
protocols. Urine analysis (including microscopy) was per-
formed in second spot urine.
Adverse event (AE) monitoring
All AEs were reported in the case report form (CRF) and
classified as mild, moderate or severe. In addition, all
serious adverse events (SAEs) were reported to the Phar-
macovigilance partner Contract Research Organization
(CRO) UBC and the respective IRB. Subjects were
instructed to contact the research nurses if they experienced
an AE. Also, the nurses questioned the subjects at each
visit about AEs. Medical records were obtained for any
SAEs that involved medical follow-up. The research nurses
followed each subject with an AE until the event was
resolved. If treatment for AEs became necessary, the
medication(s) were reported on the concomitant medica-
tion section of the CRF. AEs were presented in a frequency
table by system organ class and intervention group. In
addition, the nature, incidence, severity and cause for each
AE were reported.
Data quality assurances
Data quality was monitored by a professional monitor
(RGB Consulting, Canada) and data management by the
electronic data capture company (ClinIT, Germany).
Power analysis and statistical analyses
Determination of sample size
The primary health outcomes of this study were the effects
of GBB on change in BMD at the lumbar spine and femoral
neck. Sample size power calculations were based on the
premise that the standard deviation is not greater than
double the effect (as percent of baseline) of intervention
(see references for evidence in support of this premise)
[27–34]. As a result of these calculations, the sample size
was determined to be 30 completers per group. Assuming a
dropout rate of *15%, the final sample size was deter-
mined to be 35 per group; with this sample size, the trial
had 75% power to detect a statistically significant effect
with a type I error equal to 10% (trend).
Statistical analysis
Differences between the GBB and placebo groups were
examined using both an ANOVA model (independent t test
with equal variance) and a covariance model (ANCOVA,
including baseline values measured at visit 1 as the
covariate). Variables measured at all three visits were
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123
analyzed with the general linear model repeated measures
ANOVA. Differences were considered significant if
p \ 0.05. Safety data were evaluated by descriptive sta-
tistics, and statistically significant differences were deter-
mined by t tests (within the groups by paired t test). As
appropriate, further exploratory analyses were performed
(Pearson’s correlations between concentrations of investi-
gational products: genistein, phylloquinone, 25(OH)D and
different efficacy and safety end-points), as well as step-
wise regression analysis for determination of predictors of
BMD change.
Results
Data set, subjects demographics and screening
characteristics
Of the 70 subjects randomized, three withdrew before visit
2 and another three between visits 2 and 3. Therefore, 64
subjects were included in the per-protocol (PP) data set that
does not take into consideration compliance. There were no
statistically significant differences in baseline characteris-
tics and demographics between groups with the exception
that total cholesterol was significantly higher in the GBB
group (Table 1). All subjects experienced natural meno-
pause and had consumed no more than 2–3 dL of alcohol
daily. About half of the subjects reported using multivita-
mins, but only one quarter reported taking them regularly.
Six subjects were classified as non-compliant and were
excluded from data analysis. Consequently, the PP analysis
included 58 subjects (Fig. 1).
Bone mineral density
At the 6-month time point, subjects supplemented with the
GBB (n = 30) maintained femoral neck BMD, whereas in
the placebo group (n = 28), BMD significantly decreased
(p = 0.007, Fig. 2a), resulting in a 1.3% difference
between groups (p \ 0.05). Similarly, as shown in Fig. 2b,
there was a significant difference in BMD between the two
groups at Ward’s triangle (?2.3 vs -1.1%, p \ 0.05). The
difference in femoral neck BMD between groups remained
statistically significant in the intention to treat (ITT) anal-
ysis (p = 0.05); however, when baseline BMD was fac-
tored into the analysis, statistical significance was no
longer quite achieved (p = 0.058). The BMD delta at
Ward’s triangle, even when considering baseline BMD,
maintained statistical significance in the ITT analysis
(p = 0.002).
Table 1 Baseline characteristics and demographics at screening or baseline visits
Parameter geniVidaTM bone blend n = 31 Placebo n = 33 All ? n = 64
Age (years) 54.8 ± 2.5 54.7 ± 2.3 54.7 ± 2.4
Body weight (kg) 68.0 ± 9.2 71.1 ± 9.0 69.6 ± 9.2
BMI (kg/m2) 24.9 ± 2.8 25.9 ± 2.8 25.4 ± 2.9
Fat mass (%)a 38.0 ± 6.0 36.8 ± 6.1 37.5 ± 6.1
Years since menopause (Y) 2.2 ± 0.8 (n = 30) 2.1 ± 0.8 (n = 32) 2.1 ± 0.8 (n = 62)
Hot flashes 24/31 27/33 51/64
Hot flashes since (Y) 5.4 ± 5.8 (n = 24) 8.1 ± 10.3 (n = 27) 6.8 ± 8.5 (n = 51)
T-score (lumbar spine) -0.58 ± 1.06 -0.48 ± 1.33 -0.53 ± 1.20
T-score (hip) -0.52 ± 0.86 -0.53 ± 0.84 -0.52 ± 0.84
Previous fractures more than 1 year before inclusion 0/31 0/33 0/64
Intake of concomitant medication 24/31 26/33 50/64
Intake of multivitaminsb 15/31 14/33 29/64
Smokers 1/31 (max 10 cigarettes/day) 0/33 1/64
Systolic BP (mmHg) 114 ± 13 115 ± 11 114 ± 12
Diastolic BP (mmHg) 72 ± 9 73 ± 8 73 ± 9
Heart rate (bpm) 68 ± 7 67 ± 8 67 ± 7
Total cholesterol(mg/mL) 223.0 ± 35.4* 205.5 ± 29.0 214.0 ± 33.2
Estradiol (pg/mL) 10.2 ± 2.1 10.4 ± 3.3 10.3 ± 2.8
Follicle-stimulating hormone (mIU/mL) 109.9 ± 47.4 104.8 ± 33.7 107.3 ± 40.7
a at visit 1 (baseline); ? data only include subjects who completed the study
b About 25% of the subjects reported taking them regularly (*200 IU vitamin D and 150–300 mg Ca)
* p \ 0.5 compared to placebo
Reference ranges: Total cholesterol: \200 mg/mL
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Lumbar spine BMD decreased slightly more in women
given the placebo (-1.4%) than the GBB (-1.1%), but the
difference between groups was not statistically significant
(p = 0.55). Changes in BMD at the other sites measured
(trochanter, intertrochanter, total hip and whole body) did
not differ between groups (data not shown).
Blood and urine analytes
At both the 3- and 6-month time points, both BAP and Ntx
significantly increased in the GBB group in comparison
with those in baseline and in the placebo group (Table 2).
There were no other significant changes in bone markers
(OC, ucOC, DPD, OPG and RANKL) nor did urinary
calcium and phosphorus excretion differ between groups
(data not shown). As expected, in comparison with base-
line, total plasma genistein concentrations and EPA and
DHA increased significantly in the GBB group at 3 and
6 months, whereas there was no change in the placebo
group (Table 2). Although plasma phylloquinone concen-
trations increased from baseline to 3 months in the GBB
group, at 6 months, values were lower than at baseline, but
none of these changes were statistically significant.
Although baseline plasma 25(OH)D concentrations were in
the optimal range for both groups, suggesting that the
subjects were generally fit [35], we observed an increase at
3 months in the GBB group that was maintained to the end
of the study (Fig. 3a; Table 2). The plasma 25(OH)D
remained stable in the placebo group. Parathyroid hormone
(PTH) significantly decreased in the GBB group reflecting
the increased plasma 25(OH)D concentration (Table 3).
The season of the year during which subjects were
enrolled, which could reflect differences in sun exposure
and therefore endogenous vitamin D synthesis, had no
effect on the change in BMD at any bone site. Stepwise
regression analysis revealed that baseline BMD was the
Fig. 2 Change of bone mineral density (BMD; 6 months minus
baseline) at femoral neck (a) and Ward’s triangle (b)
Table 2 Blood analytes at different time points (PP considering compliance), mean (SD) and repeated measures ANOVA statistics











BAP (lg/L) 14.68 (4.64) 15.17 (4.38) 15.06 (4.87) 15.94 (3.96) 14.52 (3.03) 14.71 (3.93) 0.002 0.054
Ntx/crt
(nM/mM crt)
40.73 (11.75) 41.33 (12.15) 45.23 (14.17) 44.46 (13.01) 44.04 (12.54) 41.46 (12.01) ns 0.024
Genistein tot
(ng/mL)
2.1 (9.7) 96.1 (88.1) 129.8 (179.7) 4.8 (14.5) 1.5 (4.4) 2.6 (5.6) \0.001 \0.0001
25(OH)D (nM/L) 74.9 (23.0) 90.2 (16.5) 91.1 (17.8) 76.3 (22.2) 80.7 (23.1 78.1 (18.8) 0.009 0.009
Phylloquinone
(nmol/L)
2.2 (3.1) 2.6 (2.9) 2.1 (2.1) 1.5 (2.2) 1.6 (1.3) 1.2 (0.9) 0.07 ns
EPA (lg/100lL) 2.87 (1.06) Not determined 7.16 (2.86)** 4.17 (4.28) Not determined 4.09 (4.05) na 0.003*
DHA (lg/100lL) 7.29 (2.71) Not determined 11.17 (4.16)** 9.35 (5.20) Not determined 8.34 (5.59) na \0.05*
BSL Baseline, V2: 3-month visit, V3: 6-month visit, Reference range: BAP: 0–22.4 lg/L, ns nonsignificant, na not applicable, 25(OH)D
25-hydroxyvitamin D3, EPA Eicosapentaenoic acid (C20:5n-3), DHA Docosahexaenoic acid (C22:6n-3)
* Significant at V3 versus placebo
** Significant versus BSL (p \ 0.0001)
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strongest predictor of BMD after 6-month supplementa-
tion; baseline 25(OH)D did not further predict BMD. The
second most predictive factor determining BMD was GBB
independent of the season when subjects were enrolled.
This observation suggests that supplementation was suffi-
cient to counterbalance seasonal variations in vitamin D
concentrations. In addition, there was a significant rela-
tionship between plasma 25(OH)D and PTH at screening/
baseline and visit 3 (pooled data: Fig. 3b). There were no
statistically significant correlations at any of the three time
points between any blood analytes and BMD or bone
markers.
Anthropometry and dietary intake
There were no significant changes in body weight, BMI
and body fat mass in either group when comparing baseline
with final values. Similarly, there were no changes in
macro- or micronutrient intakes (Table 1). Average daily
intake of vitamin D3, calcium and n-3 fatty acids ranged
from 100 to 140 IU, 700 to 800 mg and 700 mg—4 g
(1–6% from total fat intake), respectively. According to the
dietary assessment, isoflavone intake was zero.
Safety
Laboratory findings: Clinical chemistry, hematology, lip-
ids, coagulation factors, hormones and urine analysis
(including microscopy) were analyzed in all subjects who
completed the full dosage regimen (n = 64). Total cho-
lesterol and LDL-C were above the normal reference range
at screening in both groups (Table 3), and HDL levels were
higher than the medium reference range. Although some
single determinations slightly deviated from normal values,
most laboratory parameters were well within the normal
reference range. Of note, E2 increased in the GBB group
by 12.7% (p = 0.044), but remained within the normal
range (Table 3).
Endometrial Thickness: At no time point did endome-
trial thickness (ET) differ between the groups. However,
ET significantly decreased in the GBB group between
screening and study end (2.3–1.8 mm, p = 0.007), whereas
there was no change in the placebo group (2.2–2.3 mm,
p = 0.62) and no statistical significant difference observed
between GBB and placebo at study end.
ECG and vital signs: There were no statistically sig-
nificant changes in vital signs or ECG recordings during
the course of the study in any subject, and in no case did
any change raise clinical concern.
Tolerability
Summary of adverse events: There were no significant
differences in AEs between groups. Of the total of 59 AEs
that occurred in 35 subjects, 37 were reported in 20 sub-
jects in the placebo group and 22 in 15 subjects in the GBB
group. One AE in each of three individuals led to their
withdrawal from the study, and 51% of AEs led to treat-
ment. None of the AEs were classified as severe, 66.1%
were considered mild and 33.9% as moderate. All of the
AEs except one were considered to be unrelated to the trial
supplement (98%). One moderately severe AE (abdominal
pain) was judged as probably related to the GBB supple-
ment. After withdrawal from the trial during the second
month, this symptom resolved. Approximately 80% of the
AEs resolved at study completion.
AEs were distributed over a wide range of system organ
classes (SOC); however, most of the AEs fell into the SOC
of ‘‘Infections and infestations’’ and ‘‘Reproductive system
and breast disorders.’’ The most frequently reported AE
was vaginal hemorrhage (vaginal bleeding and spotting); 5
AEs of this type occurred in 4 subjects in the placebo group
compared to one each in 2 subjects in the GBB group.
Fig. 3 25(OH)VitD concentration course with statistical significance
between GBB and placebo (a) and correlation to PTH (b)
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Serious Adverse Event (SAE): There were three cases of
incidental findings on the final vaginal ultrasounds, two in
one subject in the placebo group and one in the intervention
group. These SAEs were documented as Unanticipated
Events and unrelated to the effects of the GBB by the
investigator who reported to the IRB.
Discussion
The results of this pilot study show that GBB can reduce
bone loss in early postmenopausal women. In the placebo
group, women lost 1.2 and 1.1% BMD at the femoral neck
and Ward’s triangle, respectively, whereas women in the
GBB group gained 0.1 and 2.3% at these sites, respec-
tively. The bone maker results were unexpectedly incon-
sistent. We observed increases in both BAP and Ntx at both
the 3- and 6-month time points in the GBB group, whereas
no changes were noted in the placebo group. This was
remarkable since another bone formation marker (OC) and
one bone resorption marker (DPD) remained unchanged. In
general, the bone turnover marker BAP is decreased during
bone-sparing osteoporosis therapies, for example, bis-
phosphonates [36], hormone therapies [37] or selective
estrogen receptor modulars (SERMs). Interestingly, only
the more sophisticated therapy, using intermittent appli-
cation of a recombinant human PTH (1–34) that can
reverse bone loss, is also accompanied by increased BAP
levels [38]. We speculate that the increased bone turnover
is linked to genistein initiating bone formation [39], which
was evident after just 3 months. Bone formation is coupled
to a parallel bone resorption response, which is observed by
the increased Ntx level after 6 months. Therefore, it is
unclear why the bone formation marker OC and the
resorption marker DPD apparently remained unchanged in
the treatment group. An increase in OC and a reduction in
DPD were observed in the genistein supplementation study
of Morabito et al. [29] using a daily 54 mg dose. Inter-
estingly, when using 200 lg/days vitamin K1 alone for
6 weeks, Bu¨gel et al. [40] did not observe any effect on
bone turnover markers (total osteocalcin, BAP, Ntx and
DPD). Nevertheless, the vitamin K status markers were
improved after supplementation. The serum ucOC/cOC
ratio was significantly decreased. Interestingly, Schurgers
et al. [41] could improve the serum carboxylated/under-
carboxylated osteocalcin ratio with even a lower dose of
100 lg vitamin K1. Our study included healthy subjects
that were taking a balanced diet on the top of the GBB
supplementation. Obviously, the 150 lg vitamin K1 had no
measurable impact on their K status. As expected, plasma
levels of genistein, EPA and DHA and 25(OH)D increased
in the active group. That there were significant effects at
the femoral neck and Ward’s Triangle is especially notable
because the sample size for this study was calculated to
detect a trend, not necessarily statistically significant
effects. Therefore, the results indicate that a follow-up
study requires a sample size of only 70 subjects to confirm
the effects of the GBB at these two bone sites. However,
the results generated from this pilot study also indicate that
to detect a statistically significant effect (p \ 0.05) at the
lumbar spine would require a sample size of 900 subjects.
The findings of the present pilot study are consistent
with the majority of the published positive isoflavone
supplementation trials that also struggled with the limita-
tions of small sample size (\50 subjects/group) and short
duration (B1 years) [13–15]. Intriguingly, the four large
isoflavone studies that lasted longer than 2 years resulted in
ambiguous outcomes [16–19]. In the study by Marini et al.
[16], there were dramatic increases in postmenopausal
spinal and hip BMD in response to 54 mg/days genistein in
aglycone format. On the other hand, Levis et al. and Alekel
et al. [17, 18] that used mixtures of isoflavones in glycoside
Table 3 Blood analytes at different time points (PP, safety population), mean (SD)




Placebo (n = 33) p = V3
versus scra
scr p = GBB
versus Plcb
V3 p = GBB
versus Plcb
Screening 6 months (V3) Screening 6 months (V3)
TC (mg/mL) 223.0 (35.4) 207.8 (28.5) p = 0.014 205.5 (29.0) 195.9 (25.7) p = 0.002 p = 0.033 ns
LDL-C (mg/mL) 130.3 (33.0) 122.4 (31.7) ns 118.0 (26.7) 115.1 (24.2) ns ns ns
HDL (mg/mL) 72.3 (15.9) 67.7 (16.1) p = 0.014 68.8 (16.3) 62.1 (13.4) \0.0001 ns ns
Estradiol
(pg/mL) 10.2 (2.1) 11.5 (3.9) p = 0.044 10.4 (3.3) 10.7 (2.3) ns ns ns
PTH (pg/mL) 42.4 (13.8) 38.0 (11.4) p = 0.015 37.8 (13.3) 37.8 (14.5) ns ns ns
Scr screening, V3: 6-month visit, Reference ranges: TC: \200 mg/mL; LDL-C: \100 mg/mL; HDL: 40–59 mg/mL; Estradiol: \20 pg/mL;
PTH: 12–88 pg/mL, ns nonsignificant, TC total cholesterol, PTH parathyroid hormone
a Paired t test
b Unpaired t test
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format observed only modest or no effect at all. Both
groups used high doses of isoflavones, 80 and 120, and
200 mg/days, respectively. The contrasting results trigger
speculations that the different application formats, agly-
cone vs glycoside, could be responsible for the results due
to different bioavailability [42–44]. However, most recent
research now casts doubts on this hypothesis. Tai et al. [19]
administered 300 mg isoflavones in aglycone format and
yet did not observe skeletal benefits. An alternative
explanation is that genistein by itself functions differently
than genistein in combination with daidzein and glycitein.
Currently, there is little evidence to support this theory,
however. Another possibility could be that 80 mg and
higher doses of genistein are not beneficial; consequently,
the bone-sparing effect of genistein is negated. The in vitro
data of Dang et al. [45] point in this direction. They have
shown that isoflavones stimulate osteogenesis at low con-
centrations and inhibit osteogenesis at high concentrations
in osteoblasts and osteoprogenitor cells [45], which could
explain the observed discrepancy.
Although the current results are consistent with some
previous trials showing genistein exerts skeletal benefits,
there are important differences. For example, during the
first year of the 3-year trial by Marini et al. [16], women in
the genistein group gained 2.4% BMD at the femoral neck,
whereas women in the placebo group lost approximately
this much bone. There were also marked increases in spinal
BMD in response to genistein. The more pronounced effect
observed in that trial could be because the subjects were
osteopenic and as such had much lower baseline BMD
(e.g., femoral neck BMD, 0.0667 vs 0.740) than women in
the current trial). However, if the women in the placebo
group in the current trial continued to lose BMD at their
6-month rate over the course of 1 year, their bone loss
would have essentially matched the loss in the Italian
study. Therefore, differences in baseline BMD may not
have contributed to differences between the two studies.
An alternative and more straightforward explanation is that
the lower dose used in the current study (30 vs 54 mg/days)
accounts for the less robust results. Animal data suggest
this could be the case [46]. Differences in dose may also
explain why the current study did not show effects at the
spine whereas the study by Marini et al. [16] did. We
believe that a longer duration trial is required to see sig-
nificant effect of the GBB on spinal BMD.
It is notable that GBB supplementation had a greater
effect on Ward’s triangle than it did on the femoral neck.
Bone loss at Ward’s triangle in the placebo group was
similar to that of the femoral neck, whereas there was a
2.3% increase in the GBB group. Ward’s triangle was not
measured in the study by Marini et al. [16]. However, in an
earlier study from this group, the effect of genistein on
Ward’s triangle was slightly greater than it was on the
femoral neck. Ward’s triangle is not a true anatomic area
but is generated by the DXA scan as the area having the
lowest BMD in the femoral head. Interestingly, a small
study by Yoshihashi et al. [47] found that in men, the only
DXA BMD measurement that was sensitive for detecting
osteoporosis was Ward’s triangle. Among the women in
the current study, the DXA BMD at Ward’s triangle and
the femoral neck were equally sensitive in detecting
changes in BMD.
Because a combination of ingredients was used, it is not
possible to determine to what extent the individual com-
ponents contained in the GBB contributed to the observed
skeletal benefits. Combined calcium and vitamin D sup-
plementation has been shown to reduce fracture risk in
postmenopausal women to a greater extent than supple-
mentation with either agent alone [48]. In the current study,
the baseline plasma 25(OH)D concentrations were in the
normal range. As expected, only GBB supplementation
further increased the 25(OH)D level. Each group was
supplemented with calcium (500 mg), which when added
to their dietary intake brought their total calcium intake to
[1,200 mg/days. Interestingly, despite the rather small
study sample size, it was still possible to detect an inverse
relationship between plasma vitamin D and PTH levels
(Fig. 3b), which is consistent with previously published
data [21, 49].
In 2006, Cockayne et al. [50] reviewed the fracture risk
reduction after vitamin K supplementation in a meta-
analysis. They showed that phylloquinone and menaquin-
one-4 reduced bone loss and fracture risk. A more recent
review by Iwamoto et al. [22] also concluded that vitamin
K supplementation reduces fracture risk. However, most
trials included in this analysis used far higher doses than
the amount contained within the GBB [51]. Furthermore,
according to these authors, vitamin K works via mecha-
nisms other than by increasing BMD and affecting bone
turnover. Thus, even if the inclusion of vitamin K enhanced
the ability of the GBB to reduce fracture, the benefits may
have not been detected in the health outcomes analyzed.
The fact that there was no change in the undercarboxylated/
carboxylated osteocalcin ratio also argues against vitamin
K contributing to the increases in BMD that were observed.
Finally, in regard to omega-3 fatty acids, the evidence
that they exert skeletal benefits is intriguing but still quite
speculative [51–53]. Nevertheless, in ovariectomized rats,
Krammer [54] found that genistein (15 mg/kg bw) and n-3
PUFA (5% by weight) independently increased femoral
BMD over an 8-week period and the combined effect was
greater than the effect of either agent alone. Our study has
taken advantage of this finding and used nutritional levels
of PUFA and genistein in combination with vitamin D and
K in the GBB supplementation mixture. The results suggest
that genistein supplementation at levels that are compatible
212 Eur J Nutr (2013) 52:203–215
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with Asian isoflavone intake exerts favorable effects on
bone health although long-term trials are needed to confirm
efficacy.
The GBB was well tolerated by the subjects as there
were few AE and no SAE attributable to the intervention.
Plasma levels of E2 did increase although modestly so and
they remained within the normal range, which is generally
consistent with the literature showing that isoflavones have
little effect on estrogen levels [55]. Furthermore, and more
importantly, there were no effects of the GBB on endo-
metrial thickness. In fact, endometrial thickness decreased
over time in the GBB group although the difference in final
values between groups was not significant. Estrogen
markedly stimulates endometrial tissue and increases risk
of endometrial cancer [56]. In the previously mentioned
3-y trial by Marini et al. [16], genistein (54 mg/d) had no
effect on endometrial thickness in postmenopausal women.
In conclusion, the results of this pilot study suggest that
the use of the physiological relevant dose of genistein in
combination with EPA and DHA and vitamins D3 and K1
(GBB) may help to prevent osteoporosis and may reduce
fracture risk, at least at the hip, in postmenopausal women.
The results are also reassuring about the safety of this
product. However, additional research and especially
longer-term clinical trials are needed before definitive
conclusions can be made.
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